Monitoring antimicrobial resistance in the Democratic Republic of Congo
Surveillance of Antimicrobial Resistance in Semirural Kinshasa, Democratic Republic of Congo: a Feasibility Study
This study is testing how well we can track antibiotic resistance in a hospital in Kinshasa, DRC, to better understand bacterial infections and improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 210 (estimated) |
| Ages | 6 Months and up |
| Sex | All |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Kinshasa) |
| Trial ID | NCT06821282 on ClinicalTrials.gov |
What this trial studies
This observational study aims to fill knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa by evaluating the feasibility of AMR surveillance in a general referral hospital in semirural Kinshasa, DRC. It will investigate bacterial infections, their resistance profiles, and associated risk factors, including co-infections like malaria. The study involves training local staff in patient identification and specimen collection for AMR surveillance, with blood samples analyzed to determine bacterial causes of infections and resistance levels. Participants will be followed for 28 days post-admission to assess outcomes and improve patient management.
Who should consider this trial
Good fit: Ideal candidates include patients over six months old presenting with suspected bloodstream infections upon hospital admission.
Not a fit: Patients with significant prior healthcare exposure or contraindications for phlebotomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding and management of antimicrobial resistance, leading to better treatment outcomes for patients with bloodstream infections.
How similar studies have performed: While AMR surveillance has been studied in various contexts, this specific approach in semirural DRC is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Patients older than six months who present with a clinically suspected bloodstream infection upon admission to the hospital, or who have been hospitalized for less than 48 hours, and provide written consent (or consent from their caregiver/legal guardian) to participate will be included. Patients with a significant history of healthcare exposure and those with any contraindications for phlebotomy as determined by the clinician's judgment, will be excluded.
Where this trial is running
Kinshasa
- Kinshasa, Democratic Republic of Congo, Kinshasa School of Public Health — Kinshasa, Democratic Republic of the Congo (Recruiting)
Study contacts
- Principal investigator: Caterina Fanello, Dr. — Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom (UK)
- Study coordinator: Caterina Fanello, Dr.
- Email: caterina.fanello@ndm.ox.ac.uk
- Phone: +447900278768
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.